Health & Fitness
Health and Fitness
Health and Fitness
Tue, February 17, 2009 Experienced Cancer Researcher Joins Vitro?s Scientific Advisory Board
GOLDEN, Colo.--([ BUSINESS WIRE ])--Vitro Diagnostics, Inc. (OTCBB: VODG), dba Vitro Biopharma, announced the appointment of Dr. Pamela L. Rice to its Scientific Advisory Board. Dr. Rice holds a Ph.D. in Molecular Toxicology from the Department of Pharmaceutical Sciences at the University of Colorado and a B.S. degree in genetics from the University of California at Davis. She is presently an Assistant Professor in the Department of Medicine at the University of Colorado Health Sciences Center where she leads a team of researchers in her own laboratory that conducts grant-supported cancer research focusing on mechanism-based novel therapies.
Dr. Rice has authored numerous peer-reviewed papers in her nearly 20-year career as a cancer researcher in journals including "Cancer Research" and "Molecular Cancer Therapeutics." Her research includes detailed studies of the mechanisms of cancer cell death induced by non-steroidal anti-inflammatory drugs and novel therapeutic targets for colon cancer. The latter includes pathways involved in regulating cell proliferation and cell survival.
Dr. Rice will provide Vitro with consultation in the development of its stem cell products and technology for application to cancer research and treatment. Dr. Rice said, "I am excited to have the opportunity to apply my extensive experience and expertise to assist Vitro in the development of novel stem cell-based products for the fight against cancer. Cellular-mediated destruction of cancer stem cells represents a promising new avenue for the development of effective treatments that specifically target cancer stem cells. This is important because new ways to attack difficult to treat cancers continue to involve stem cell-mediated mechanisms. Additionally, these new products would minimize side-effects of standard chemotherapy. The products that Vitro is developing may provide cancer researchers with more selective tools to advance this very important new approach to cancer treatment."
Vitro owns issued US patents for production of FSH, a fertility drug, immortalization of cells and recently received a Notice of Allowance for its patent for generation of adult stem cells. In addition, the Company has another pending US patent regarding stem cell-based cancer treatments.
Dr. Joe Nieusma, also a member of Vitro's SAB and consultant to Vitro, said, "I am enthusiastic about the appointment of Dr. Rice to Vitro's SAB and scientific team. Her background in cancer research, cell culture and in vivo mechanistic work provides tremendous expertise that complements Vitro's existing talents and will aid in advancing the excellent stem cell research program already in existence. I anticipate synergy between Dr. Rice and Vitro that will accelerate development of novel stem cell-based cell therapies for cancer, especially traditionally poor prognosis cancers such as pancreatic, lung and brain."
About Vitro Diagnostics, Inc.
Vitro Diagnostics, Inc., dba Vitro Biopharma (OTCBB: VODG)([ http://www.vitrodiag.com ]), is committed to "Harnessing the Power of Cells" and owns proprietary technology, cell lines and related products with potential application to treatment of cancer, diabetes and infertility. Vitro recently established a new, high tech and regulatory-compliant manufacturing, R&D and corporate facility in Golden, Colorado. The current focus is development and commercialization of adult stem cell products for use in diabetes research, pharmaceutical product development and therapies to treat type I diabetes. In addition, Vitro's stem cell technology has shown promise for development of targeted cancer therapies using stem cell-mediated mechanisms to attack difficult to treat malignancies including those of the pancreas, lung and brain.
Safe Harbor Statement
Certain statements contained herein and subsequent oral statements made by and on behalf of the Company may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are identified by words such as "intends," "anticipates," "believes," "expects" and "hopes" and include, without limitation, statements regarding the Company's plan of business operations, product research and development activities, potential contractual arrangements, receipt of working capital, anticipated revenues and related expenditures. Factors that could cause actual results to differ materially include, among others, acceptability of the Company's products in the market place, general economic conditions, receipt of additional working capital, the overall state of the biotechnology industry and other factors set forth in the Company's Annual Report on Form 10-KSB for the fiscal year ended October 31, 2007 under the caption, "Risk Factors" and subsequent SEC filings. Most of these factors are outside the control of the Company. Investors are cautioned not to put undue reliance on forward-looking statements. Except as otherwise required by applicable securities statutes or regulations, the Company disclaims any intent or obligation to update publicly these forward-looking statements, whether as a result of new information, future events or otherwise.
